Document is current
Any future updates will be listed below
-
Authors
Singh, Jasvinder A. https://orcid.org/0000-0003-3485-0006
Cleveland, John D.
-
Funding
Funding for this research was provided by:
research funds from the Division of Rheumatology at the University of Alabama at Birmingham (No Number)
the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama, USA (No number)
- License Information
-
More Information
Article History
Received: 20 October 2019
Revised: 16 November 2019
Accepted: 29 November 2019
First Online: 2 January 2020
Compliance with ethical standards
:
: The funding body did not play any role in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.
: JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, the National Institutes of Health, and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. DC has no conflicts to declare. There are no non-financial competing interests for any of the authors.
: The University of Alabama at Birmingham’s Institutional Review Board approved this study and waived the need for informed consent for this database study (X120207004). All investigations were conducted in conformity with ethical principles of research.
